Farmas USA

* MERCK ANNOUNCES SECOND-QUARTER 2020 FINANCIAL RESULTS
    * Q2 NON-GAAP EARNINGS PER SHARE $1.37
    * Q2 GAAP EARNINGS PER SHARE $1.18
    * Q2 EARNINGS PER SHARE ESTIMATE $1.04 -- REFINITIV IBES
DATA
    * COMPANY NARROWS AND RAISES 2020 FULL-YEAR REVENUE RANGE TO
BE
BETWEEN $47.2 BILLION AND $48.7 BILLION
    * COMPANY NARROWS AND RAISES 2020 FULL-YEAR GAAP EPS RANGE
TO BE
BETWEEN $4.58 AND $4.73
    * QTRLY KEYTRUDA SALES GREW 29% TO $3.4 BILLION
    * NARROWS AND RAISES 2020 FULL-YEAR NON-GAAP EPS RANGE TO BE
BETWEEN $5.63 AND $5.78
    * SECOND-QUARTER 2020 WORLDWIDE SALES WERE $10.9 BILLION, A
DECREASE OF 8%
    * Q2 REVENUE VIEW $10.39 BILLION -- REFINITIV IBES DATA
    * QTRLY JANUVIA / JANUMET SALES $1.34 BILLION VERSUS $1.44
BILLION
REPORTED LAST YEAR
    * QTRLY GARDASIL / GARDASIL 9 SALES $656 MILLION VERSUS $886
MILLION REPORTED LAST YEAR
    * FY2020 EARNINGS PER SHARE VIEW $5.31, REVENUE VIEW $47.33
BILLION -- REFINITIV IBES DATA
    * V591 IS CURRENTLY IN PRECLINICAL DEVELOPMENT AND CLINICAL
STUDIES ARE PLANNED TO START IN Q3
    * V590 IS CURRENTLY IN PRECLINICAL DEVELOPMENT AND CLINICAL
STUDIES ARE PLANNED TO START THIS YEAR.
    * IN Q2, ESTIMATED OVERALL NEGATIVE IMPACT OF COVID-19
PANDEMIC TO
MERCK'S REVENUE WAS APPROXIMATELY $1.6 BILLION
    * FOR 2020, NOW EXPECTS UNFAVORABLE IMPACT TO REVENUE OF
ABOUT
$1.95 BILLION (EXCLUDING IMPACT OF FOREIGN EXCHANGE) DUE TO
COVID-19 PANDEMIC

• Gilead Sciences (NASDAQ:GILD) Q2 results:
• Total revenues: $5,143M (-9.5%); product sales: $5,067M (-9.7%); HIV: $4,000M (-1.0%).
• Sales were pressured by pandemic-related disruptions affecting HCV products and generic encroachment on Letairis and Ranexa.
• Top sellers: Biktarvy: $1,604M (+43.7%); Genvoya: $816 (-16.7%); Truvada: $387M (-46.1%); Yescarta: $156M (+30.0%).
• Net income: ($3,339M) (-277.6%); non-GAAP net income: $1,400M (-36.2%); EPS: ($2.66) (-281.0%); non-GAAP EPS: $1.11 (-35.5%).
• 2020 guidance: Product sales: $23.0B - 25.0B from 21.8B - 22.2B; EPS: $0.83 - 2.23 from $5.15 - 5.55; non-GAAP EPS: $6.25 - 7.65 from $6.05 - 6.45